Crohn's Montreal Classification: A, L, B, and p Explained

An entry such as “A2 L3 B2p” in a Crohn’s record is a phenotype description, not a current activity score. The Montreal classification records age at diagnosis, disease location, disease behavior, and a perianal modifier. It does not calculate symptoms, CRP, fecal calprotectin, or colonoscopy severity. The code can remain stable while inflammation improves, and the behavior portion can change as complications develop. Knowing that difference prevents a common mistake: reading B2 or L3 as a flare grade (Montreal-classified cohort).

A is age at diagnosis

A1 means diagnosis at age 16 or younger. A2 means age 17 through 40, and A3 means older than 40. This is age when Crohn’s was diagnosed, not current age. The category therefore does not advance on a birthday. It gives researchers and clinicians standardized phenotype context because age at diagnosis can be associated with patterns of disease (Montreal-classified cohort).

Pediatric records may use the Paris classification, a modification that separates younger age groups, refines upper gastrointestinal location, allows combined stricturing and penetrating behavior, and adds growth information (Paris classification paper; Paris classification cohort). This is another reason to preserve the name of the system, not only the letters.

L is location

L1 is ileal disease, allowing limited cecal involvement. L2 is colonic disease. L3 is ileocolonic disease. L4 denotes upper gastrointestinal involvement and can be added as a modifier to L1, L2, or L3 rather than replacing them. Location is based on the maximum documented extent under the classification rules, so a later normal-looking segment after treatment does not necessarily erase the established phenotype (Montreal application study).

Location is not the same as activity. Someone classified L3 may have deep remission, mild activity, or a severe flare. CRP and calprotectin do not determine L1 through L4. Endoscopy and imaging scores are used when the question is how active disease looks now.

B is behavior, and p marks perianal disease

B1 means non-stricturing, non-penetrating behavior, sometimes called inflammatory. B2 means stricturing disease. B3 means penetrating disease, such as internal fistulizing complications. The lowercase p modifier records perianal disease separately. Perianal disease alone does not automatically make the luminal behavior B3 under Montreal rules (Montreal application study).

Behavior can evolve. Longitudinal work with the earlier Vienna framework found location relatively stable while behavior changed more often toward stricturing or penetrating patterns (Crohn’s behavior study). A record may therefore be updated from B1 to B2 or B3 as new evidence appears. Established stricturing or penetrating history is not generally “downgraded” simply because treatment controls current inflammation.

For tracking, save the full code, classification system, date assigned, and evidence used. Keep operative reports, imaging, endoscopy, and perianal history nearby. Separately track symptoms, CRP, calprotectin, and activity scores so a stable phenotype is not mistaken for a static disease state. The Montreal code is a compact map of where Crohn’s has been and how it has behaved. It does not tell you, by itself, how inflamed the bowel is today or whether treatment is working.

Questions that make the number more useful

Before comparing this result with an older one, confirm that both records used the same named instrument, version, scoring range, and assessment window. Ask whether the total represents the worst segment, a sum across segments, an average, or a single day. If a clinician or study used a modified version, record exactly what was removed or added. Also check whether treatment, bowel preparation, infection, missed diary entries, or incomplete examination affected the inputs. A small apparent change may reflect measurement conditions rather than a meaningful change in disease.

At a visit, useful questions include: What domain does this score measure? Which component drove the result? What would count as response or remission in this setting? Does the number need confirmation with blood work, stool testing, endoscopy, biopsy, or imaging? Is the goal to follow symptoms, current inflammation, structural damage, treatment response, or quality of life? Asking these questions turns an unfamiliar total into a specific clinical conversation.

For personal tracking, avoid combining unlike scores on one graph. Keep each instrument in its own series and place objective tests on parallel timelines. Save the source report because the component details may matter later. Note both the sample or procedure date and the date you received the result. Trends are easiest to interpret when the method and timing stay consistent. If the number conflicts with how you feel or with another test, bring the disagreement to your care team instead of choosing the result that seems most reassuring. Discordance is often the reason to look more closely.